Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Strikes Deals with Bayer, Lilly; Hires Vuko

Premium

P

ALO ALTO, Calif.--Incyte Pharmaceuticals won another LifeSeq subscriber last week and expanded its licensing arrangement with an existing subscriber. In a new deal, Bayer subscribed to the LifeSeq Gold database for therapeutic protein discovery, gaining access to Incyte’s portfolio of more than 50,000 genes. Incyte did not reveal terms of the deal, and said only that it could receive future milestone payments and royalties on product sales.

Meanwhile, Eli Lilly, which already subscribed to the LifeSeq Gold product, extened its agreement to become the first subscriber to Incyte’s database of single-nucleotide polymorphisms.

Separately, Incyte has hired John Vuko as its new CFO to replace Denise Gilbert who resigned last year. Vuko had previously been CFO at Achievement Radio Holdings and Ross Stores, and held various positions with the Cooper family of companies.

Filed under

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.